Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SBT 020

Next Previous
Search
Drug Profile

SBT 020

Alternative Names: SBT-020; SBT-020-01; SBT-20; SS 20 - Stealth BioTherapeutics; SS-20

Latest Information Update: 28 Jan 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cornell University; Institut de recherches cliniques de Montreal
  • Developer Stealth BioTherapeutics
  • Class Neuroprotectants
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported CNS disorders; Huntington's disease; Peripheral nervous system diseases

Most Recent Events

  • 28 Jan 2023 No recent reports of development identified for preclinical development in Peripheral-nervous-system-diseases in USA
  • 23 Feb 2022 No development reported - Phase-II for Huntington's disease (Early-stage disease) in Netherlands (SC)
  • 13 May 2021 Stealth BioTherapeutics has patent pending protection for SBT 020 in Europe before May 2021

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top